ctDNA-styret kantsten til OPD MNSCLC på TKI (Curb-TKI) (CURB-TKI)
En fase II Open-Label-forsøg: ctDNA-styret kantsten til OPD MNSCLC på TKI (CURB-TKI)
This is an open-label, prospective single arm Phase II trial that investigates the role of ablative stereotactic body radiation therapy (SBRT) in oncogene driven metastatic non-small cell lung cancer (mNSCLC) patients with oligoprogressive disease (OPD) on targeted therapy (TKI) followed by circulating tumor DNA (ctDNA) analysis for tailoring targeted therapies.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Fase 2
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: C. Jillian Tsai
- Telefonnummer: 4866 416-946-4501
- E-mail: jillian.tsai@uhn.ca
Studiesteder
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 2M9
- Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network
-
Kontakt:
- Jillian Tsai
- Telefonnummer: 4866 416-946-4501
- E-mail: jillian.tsai@uhn.ca
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Age 18 or older.
- Able to do most daily activities (ECOG 0-2).
- Able and willing to sign an informed consent form to join the study.
- Metastatic disease detected on imaging and histologically confirmed NSCLC on first-line TKI therapy
- Willing to give a blood sample for ctDNA analysis.
- No upper limit to the number of total metastatic sites, but a maximum of five progressive metastatic sites, inclusive of primary disease and metastatic lesions, all of which must be extracranial
- Prior radiation therapy near progressive lesions is allowed if applicable.
- All sites of oligoprogression that can be safely treated with SBRT or hypofractionated ablative radiotherapy
- Oligoprogressive disease is evaluated independently for each lesion using specific criteria.
- Stable brain metastases allowed if asymptomatic and do not require corticosteroids.
- Oligoprogressive lesions previously treated with external beam radiation are eligible as long they are clinically asymptomatic, and re-treatment is possible according to the investigator. Prior conventional, non-stereotactic radiotherapy for palliative -purposes is allowed, and if the palliated lesion subsequently progressed but remains asymptomatic and does not require immediate radiotherapy, the lesion can still be counted toward one of the five oligoprogressive lesions
- Participant is able (i.e. sufficiently fluent or with the assistance of a translator) and willing to complete the quality of life and/or health utility questionnaires in English
- Accessible for treatment and follow-up.
Exclusion Criteria:
- More than 5 extracranial sites of progressive disease.
- Pregnant.
- Leptomeningeal disease.
- Serious health issues that prevent radiotherapy, like ataxia-telangiectasia or scleroderma.
- Prior radiation therapy near the progressive lesion that would prevent treatment with SBRT due to exceeding limits of healthy tissue tolerance.
- Any other condition that the investigator believes makes participation in the study inappropriate.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomiseret
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: Decreasing or undetectable ctDNA levels after SBRT/high-dose radiotherapy
This group continues the same first-line standard of care or targeted systemic therapy after completion of SBRT. |
SBRT/high-dose radiotherapy Standard of care targeted therapy SBRT/high-dose radiotherapy Second-line targeted therapy |
|
Eksperimentel: Persistent or increasing ctDNA levels after SBRT/high-dose radiotherapy
This group of patients will be switched to a different targeted therapy (second line) or standard of care systemic therapy after completion of SBRT. |
SBRT/high-dose radiotherapy Standard of care targeted therapy SBRT/high-dose radiotherapy Second-line targeted therapy |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Progression-free-survival
Tidsramme: 1 year
|
Progression-free-survival 1 (PFS1) will be determined from the first day of SBRT to oligoprogressive sites to the day of diagnosis of radiological progression in the subsequent imaging (irrespective of change in systemic therapy in group B, essentially second-line) or death |
1 year
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Subsequent progression-free-survival
Tidsramme: 1 year
|
Subsequent PFS will be calculated from the date of first radiological progression after SBRT to second radiological progression or change to 3rd line systemic therapy or death or loss to follow-up, whichever comes first. |
1 year
|
|
Acute and Late Toxicities
Tidsramme: 1 year
|
For SBRT combined with TKI (using CTCAE Version 5.0) |
1 year
|
|
Reported Adverse Events
Tidsramme: 1 year
|
PRO-CTCAE Questionnaire |
1 year
|
|
Quality of Life Outcome
Tidsramme: 1 year
|
QLQ-LC13 Questionnaire |
1 year
|
|
Quality of Life Outcome
Tidsramme: 1 year
|
EORTC-QLQ-C15 Questionnaire |
1 year
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Anslået)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- 24-6091
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .